Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...